Nektar Therapeutics (NKTR) News & Overview - Discounting Cash Flows
NKTR
Nektar Therapeutics
NKTR (NASDAQ)

NKTR's Business Model

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Sector & Industry Healthcare / Biotechnology
Website https://www.nektar.com
CEO (Chief Executive Officer) Howard W. Robin
Number of Employees
IPO date May 3, 1994

NKTR Latest News

Contact
CountryUS
Address455 Mission Bay Boulevard South
CitySan Francisco
StateCA
Phone415 482 5300
Zip Code94158
Other Identifiers
CIK0000906709
ISINUS6402683063
CUSIP640268306
Open23.81
Previous Close23.47
Volume1.45 Mil.
Average Volume1.67 Mil.
Day’s Range21.87 – 23.9799
52 Week Range6.45-37.38
MA (50)13.2732
MA (200)14.47605
Market Cap282 Mil.
Shares Out.12.41 Mil.
Earnings DateAug 06, 2025
Beta
Last Dividend
EPS
PE

Industry Competitors for NKTR

discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us